J&J CEO says curing certain cancers within a decade is realistic
Key takeaways
- Duato made the remarks on Wednesday at the WSJ Leadership Institute CEO Summit in London.
- On the technology front, Duato said AI has begun accelerating J&J's drug development process, though how much financial benefit the company will ultimately realize from it remains unclear.
- "We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors."
J&J CEO says curing certain cancers within a decade is realistic Quartz · Jeff Schear / Getty Images Colleen Cabili Tue, June 16, 2026 at 11:48 PM GMT+7 2 min read JNJ Within ten years, curing some cancers outright and managing others as long-term conditions is an achievable ambition, J&J Chairman and CEO Joaquin Duato said, according to The Wall Street Journal.
Duato made the remarks on Wednesday at the WSJ Leadership Institute CEO Summit in London. Eradicating cancer entirely and helping people live longer, healthier lives represents the company's ultimate goal, Duato added.
Reaching the top spot in oncology by 2030 is among J&J's stated targets, with deals in the pipeline expected to bring new cancer treatment platforms into the company's portfolio over the next several years, according to the Journal. On the technology front, Duato said AI has begun accelerating J&J's drug development process, though how much financial benefit the company will ultimately realize from it remains unclear.